Table 2

IMDC-related characteristics in patients treated with vedolizumab and infliximab alone (N=156)

CharacteristicVedolizumab n=62Infliximab n=94P value
Median length of ICI treatment, days (IQR), n=15673 (28–247)70 (28–151)0.846
Median time from ICI initiation-IMDC onset, days (IQR), n=156104 (53–212)96 (33–188)0.065
No of ICI treatments before IMDC, mean (SD)7 (8)7 (6)0.235
Diarrhea grade, no (%)0.583
1–220 (32)33 (35)
3–442 (68)61 (65)
Colitis grade, no (%)0.246
1–230 (48)57 (61)
3–432 (52)37 (39)
Median duration of initial IMDC symptoms, days (IQR), n=15656 (27–80)50 (31–69)0.054
Endoscopy evaluation, no (%)60 (96)65 (69)<0.001
Endoscopic presentation, no (%)0.265
Mucosal ulceration17 (28)19 (29)
Non-ulcerative inflammation32 (54)37 (57)
Normal11 (18)9 (14)
Histology features–no (%)0.105
Acute active colitis12 (20)24 (37)
Chronic active colitis35 (58)31 (48)
Microscopic colitis13 (22)10 (15)
IV steroids, no (%)36 (58)58 (62)0.237
Median duration of steroids for initial IMDC, days (IQR), n=15635 (27–43)51 (41–68)<0.001
No of steroid tapering attempts prior to SIT use, median (IQR), n=1561 (1–3)2 (2–3)0.016
Median duration from IMDC to first dose of SIT- days (IQR), n=15611 (9–48)23 (19–37)<0.001
No of SIT doses (%)<0.001
1–221 (34)77 (82)
≥341 (66)17 (18)
Doses of SIT, mean (SD)3 (2)2 (1)<0.001
Median duration from first dose of SIT to symptom remission or improvement to grade 1, days (IQR), n=13818 (10–40)13 (8–29)0.012
Hospitalization, no (%)40 (65)67 (71)0.367
Median duration of hospitalization, days (IQR), n=10710 (5–15)14 (8–19.8)0.043
Multiple hospitalizations, no (%)10 (16)26 (28)0.005
Clinical remission, no (%)55 (89)83 (88)0.785
Recurrent IMDC, no. (%)8 (14)27 (29)0.007
Immunosuppressant-associated infection, no (%)12 (19)23 (25)0.184
  • ICI, immune checkpoint inhibitor; IMDC, immune-mediated diarrhea and colitis; IV, intravenous; SIT, selective immunosuppressive therapy.